About 15 results found for searched term "FXR agonist 5" (0.123 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M42407 | FXR agonist 5 | Farnesoid X Receptor |
| FXR agonist 5 is a FXR agonist. | ||
| M2165 | WAY-362450 (Turofexorate isopropyl) | Farnesoid X Receptor |
| XL335; FXR-450 | ||
| WAY-362450 (Turofexorate isopropyl; XL335) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM. | ||
| M2204 | T0901317 | Liver X Receptor |
| T0901317 is a potent and selective agonist for both LXRα and LXRβ with an EC50 of 20~50 nM. T0901317 activates FXR with an EC50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively. | ||
| M3775 | Obeticholic Acid (INT-747) | Farnesoid X Receptor |
| 6-ECDCA; UNII-0462Z4S4OZ; OCA; 6-Ethylchenodeoxycholic acid | ||
| Obeticholic Acid (INT-747) is a potent, orally active, selective farnesoid X receptor (FXR) agonist with an EC50 of 99 nM.May be used in studies related to non-alcoholic steatohepatitis (NASH). | ||
| M6302 | Fexaramine | Farnesoid X Receptor |
| Fexaramine is a selective farnesoid X receptor (FXR) agonist with EC50 of 25 nM, with 100-fold increased affinity relative to natural compounds. | ||
| M9039 | Cilofexor | Farnesoid X Receptor |
| GS-9674; PX-104 | ||
| Cilofexor is a potent, selective, orally active non-steroidal farnesoid X receptor (FXR) agonist with an EC50 value of 43 nM. It has anti-inflammatory activity and may be studied in primary sclerosing cholangitis (PSC) and non-alcoholic steatohepatitis (NASH). | ||
| M9124 | DY268 | Farnesoid X Receptor |
| DY-268 | ||
| DY268 is a potent FXR antagonist with IC50 of 7.5 nM. DY268 can be used in the study of drug-induced liver injury (DILI). | ||
| M10940 | LY2562175 | Farnesoid X Receptor |
| TERN-101 | ||
| LY2562175 is an effective and selective FXR agonist EC50 The value is 193 nM. | ||
| M10947 | INT-767 | Others |
| INT-767 is a farnidol X receptor (FXR)/TGR5 dual agonist,EC50 The values are 30 and 630 nM, respectively. | ||
| M11004 | GSK-2324 | Others |
| GSK2324 is a FXR agonist with EC50 value of 50 nM. | ||
| M13379 | Guggulsterone | Apoptosis |
| Z/E-Guggulsterone | ||
| Guggulsterone is a plant sterol from the gum fat of the Commiphora Wightii tree. Guggulsterone is a farnesoid X receptor (FXR) antagonist, decreases CDCA-induced FXR activation with IC50s of 17 and 15 μM for Z- and E-Guggulsterone, respectively. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt. | ||
| M21185 | BMS-986318 | Farnesoid X Receptor |
| BMS-986318 is a potent non-bile acid FXR agonist with an EC50 of 53 and 350 nM in FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has suitable ADME properties and is effective in a mouse model of hepatic cholestasis and fibrosis with bile duct ligation.BMS-986318 can be used in nonalcoholic steato BMS-986318 can be used in non-alcoholic steatohepatitis (NASH) studies. | ||
| M22512 | EDP-305 | Farnesoid X Receptor |
| EDP305 | ||
| EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 can be used for the research of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). | ||
| M31160 | HEC96719 | Farnesoid X Receptor |
| HEC-96719 | ||
| HEC96719 is a novel, selective, orally active tricyclic FXR agonist that activates FXR and induces expression of the target genes FGF15 and BSEP for nonalcoholic steatohepatitis (NASH) studies. | ||
| M42371 | Tauro-α-muricholic acid sodium | Metabolite/Endogenous Metabolite |
| Tauro-α-muricholic acid (T-α-MCA) sodium is a FXR (Farnesoid X receptor) antagonist (IC50=28μM). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
